» Articles » PMID: 38194019

Depression Promotes Breast Cancer Progression by Regulating Amino Acid Neurotransmitter Metabolism and Gut Microbial Disturbance

Overview
Specialty Oncology
Date 2024 Jan 9
PMID 38194019
Authors
Affiliations
Soon will be listed here.
Abstract

Introduction: Breast cancer (BC) is the most prevalent type of cancer and has the highest mortality among women worldwide. BC patients have a high risk of depression, which has been recognized as an independent factor in the progression of BC. However, the potential mechanism has not been clearly demonstrated.

Methods: To explore the correlation and mechanism between depression and BC progression, we induced depression and tumor in BC mouse models. Depression was induced via chronic unpredictable mild stress (CUMS) and chronic restraint stress (CRS). Amino acid (AA) neurotransmitter-targeted metabonomics and gut microbiota 16S rDNA gene sequencing were employed in the mouse model after evaluation with behavioral tests and pathological analysis.

Results: The tumors in cancer-depression (CD) mice grew faster than those in cancer (CA) mice, and lung metastasis was observed in CD mice. Metabonomics revealed that the neurotransmitters and plasma AAs in CD mice were dysregulated, namely the tyrosine and tryptophan pathways and monoamine neurotransmitters in the brain. Gut microbiota analysis displayed an increased ratio of Firmicutes/Bacteroides. In detail, the abundance of f_Lachnospiraceae and s_Lachnospiraceae increased, whereas the abundance of o_Bacteroidales and s_Bacteroides_caecimuris decreased. Moreover, the gut microbiota was more closely associated with AA neurotransmitters than with plasma AA.

Conclusion: Depression promoted the progression of BC by modulating the abundance of s_Lachnospiraceae and s_Bacteroides_caecimuris, which affected the metabolism of monoamine neurotransmitters in the brain and AA in the blood.

Citing Articles

Post-marketing safety of elacestrant in breast cancer: a pharmacovigilance investigation using the FDA adverse event reporting system.

Fan Z, Xu Y, Guo S, Song B BMC Pharmacol Toxicol. 2025; 26(1):56.

PMID: 40069893 PMC: 11895172. DOI: 10.1186/s40360-025-00887-2.


Risk factors and prediction model for sub-threshold depression in young and middle-aged breast cancer patients.

Li J, Wang Y, Guo J, Jin L Am J Transl Res. 2025; 16(12):7542-7552.

PMID: 39822554 PMC: 11733342. DOI: 10.62347/BIYK4324.


The gut microbiome in patients with Cushing's disease affects depression- and anxiety-like behavior in mice.

Nie D, Wang D, Wang Z, Fang Q, Wang H, Xie W Microbiome. 2024; 12(1):225.

PMID: 39482760 PMC: 11529176. DOI: 10.1186/s40168-024-01939-1.

References
1.
Sung H, Ferlay J, Siegel R, Laversanne M, Soerjomataram I, Jemal A . Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA Cancer J Clin. 2021; 71(3):209-249. DOI: 10.3322/caac.21660. View

2.
Pilevarzadeh M, Amirshahi M, Afsargharehbagh R, Rafiemanesh H, Hashemi S, Balouchi A . Global prevalence of depression among breast cancer patients: a systematic review and meta-analysis. Breast Cancer Res Treat. 2019; 176(3):519-533. DOI: 10.1007/s10549-019-05271-3. View

3.
Wang Y, Li J, Shi J, Que J, Liu J, Lappin J . Depression and anxiety in relation to cancer incidence and mortality: a systematic review and meta-analysis of cohort studies. Mol Psychiatry. 2019; 25(7):1487-1499. DOI: 10.1038/s41380-019-0595-x. View

4.
Pavlova N, Thompson C . The Emerging Hallmarks of Cancer Metabolism. Cell Metab. 2016; 23(1):27-47. PMC: 4715268. DOI: 10.1016/j.cmet.2015.12.006. View

5.
Contorno S, Darienzo R, Tannenbaum R . Evaluation of aromatic amino acids as potential biomarkers in breast cancer by Raman spectroscopy analysis. Sci Rep. 2021; 11(1):1698. PMC: 7813877. DOI: 10.1038/s41598-021-81296-3. View